These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30872077)

  • 1. P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy.
    Fernández-Aroca DM; Roche O; Sabater S; Pascual-Serra R; Ortega-Muelas M; Sánchez Pérez I; Belandia B; Ruiz-Hidalgo MJ; Sánchez-Prieto R
    Cancer Lett; 2019 Jun; 451():23-33. PubMed ID: 30872077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
    Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
    Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK4/6 inhibitor protects chemerin-induced human granulosa-lutein cells from apoptosis by inhibiting the p53/p21
    Li Y; Zhang L; Shan Y; Jia C; Xu Y
    Mol Reprod Dev; 2019 Nov; 86(11):1561-1568. PubMed ID: 31339188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
    Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
    Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
    Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
    Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
    Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P
    Oncogene; 2019 May; 38(21):4125-4141. PubMed ID: 30700828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
    Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
    Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
    Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
    Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
    Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
    J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice.
    Lee CL; Oh P; Xu ES; Ma Y; Kim Y; Daniel AR; Kirsch DG
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1569-1576. PubMed ID: 30056081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
    Zhang J; Zhou L; Zhao S; Dicker DT; El-Deiry WS
    Cell Cycle; 2017 Jun; 16(12):1193-1200. PubMed ID: 28486050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
    Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
    Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
    Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.